Back to News
Market Impact: 0.25
Radiopharm Doses First Patient In Second Cohort Of Phase 1/2a RV-01 Trial
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Radiopharm Theranostics (RADX) dosed the first patient in the second cohort of its Phase 1/2a first-in-human trial of BetaBart (RV-01) in patients with B7-H3-expressing solid tumors. This is an early clinical milestone indicating continued progression of the program, though full safety/efficacy readouts are still pending.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
RADX0.25
More News
- Kimberly-Clark is having its best week in four years. Here's what is propelling shares higher
- Semiconductors are out, software is in. Why that’s not about to change anytime soon
- After years of U.S. export bans, China plans its own: 40 AI, chip and solar technologies could be restricted
- Qatar will help revive Lebanon’s economy by fixing its power grid and rebuilding the war-damaged south, prime minister said
- Europe's answer to SpaceX set for 25% weekly gain as Ukraine's Starshield limits raise concerns
- Here's how the CoreWeave sell-off is affecting OpenAI vs. Anthropic valuations